ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Completed · Phase 1 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

This is a Phase 1, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALT-801 and its effects on glucose control in overweight and obese subjects with type 2 diabetes mellitus (T2DM).

Key facts

Study ID
NCT05134662
Run by
Altimmune, Inc.
People needed
55
Starts
2022-02-01
Expected to finish
2023-03-09
Last updated by the study team
2025-06-24

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.